- Facilitates genome-wide analysis of DNA-protein interactions
- Simplifies chromatin immunoprecipitation and sequencing library construction
- Contains validated reagents, protocols, and quality control guidelines
Billerica, MA—May 17, 2011 — EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced the launch of the Magna ChIP-Seq preparation kit designed to simplify genome-wide profiling of DNA-protein interactions by chromatin immunoprecipitation and next generation sequencing (ChIP-Seq).
“Genome-wide mapping of DNA-protein interactions using ChIP-Seq is indispensible for many gene regulation studies but the techniques can be challenging,” notes John Rosenfeld, Ph.D., manager, Chromatin Biology Group, EMD Millipore. “With the all-in-one Magna ChIP-Seq kit, this process is now simplified, enabling both experienced and new labs to more effectively leverage this powerful technique.”
In contrast to other products that support only part of the ChIP-Seq workflow, the Magna ChIP-Seq kit is a complete solution that provides a set of validated reagents for both chromatin immunoprecipitation and next generation library construction. These reagents, in combination with a detailed protocol and quality control guidelines, simplify the ChIP-Seq process to allow researchers to map interactions of histones, transcription factors, and other chromatin associated proteins on a genome-wide scale.
As successful immunoprecipitation is critical to construction of the sequencing library, the kit includes positive and negative control antibodies and a set of PCR primers that can be used as in-process controls or to verify technique. The kit has been used to construct ChIP-Seq libraries from as little as 1 ng of purified ChIP DNA, meaning that DNA segments associated with low abundance proteins can be sequenced.
For more information on Magna ChIP-Seq kit, please visit www.millipore.com/chipseq.
About EMD Millipore
EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.
Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany
Contact:
Leslie Eisenberg (Feinstein Kean Healthcare)
Phone: +1 617 244 3872
Email: [email protected]